{
  "chapter": "Miscellaneous-Transplantation",
  "questions": [
    {
      "q_no": 1,
      "question": "A 52-year-old woman, who underwent a liver transplant 2 months ago, presents with jaundice and bile leakage from the surgical site. Imaging studies suggest narrowing of the bile ducts. What is the most likely complication she is experiencing, and what could be the potential need for management?",
      "options": {
        "A": "Acute cellular rejection- Increase immunosuppressants",
        "B": "Chronic rejection- Continue monitoring",
        "C": "Ischemic-type biliary lesion (ITBL)- Consider retransplantation",
        "D": "Hepatic artery thrombosis- Start anticoagulation therapy"
      },
      "correct_answer": "C",
      "explanation": "Ischemic-type biliary lesion (ITBL); Consider retransplantation: It is a severe form of biliary stricture that can occur after liver transplantation, often leading to bile leaks and jaundice. In severe cases, it may necessitate retransplantation. Complications and Retransplantation Indications Complication Description Retransplant Indication Primary Non-function (PNF) Transplanted liver fails to function. Often required. Hemorrhage Bleeding due to portal hypertension or coagulopathy. Not usually indicated unless severe. Hepatic Artery Thrombosis (Option D) Blockage of the hepatic artery. Often required, especially if early onset. Biliary Complications (Option C) Bile leaks, strictures, or ischemic-type biliary lesions. Required in severe cases like ITBLs. Acute Cellular Rejection (Option A) The immune system attacks the liver. Usually managed with medication. Chronic Rejection (Option B) Gradual loss of graft function over time. May eventually require retransplant. Reference: Bailey & Love’s Short Practice of Surgery, 28th Edition, Page 1617, 1618.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 2,
      "question": "A 55 y/o male with advanced idiopathic pulmonary fibrosis (IPF) is evaluated for lung transplantation. He has significant dyspnea on minimal exertion, and his forced vital capacity (FVC) is 42% of the predicted value. His pre-transplant workup is normal, and he is listed for a single lung transplant. Which of the following conditions is most likely to benefit from single lung transplantation?",
      "options": {
        "A": "Cystic fibrosis",
        "B": "Pulmonary arterial hypertension",
        "C": "Idiopathic pulmonary fibrosis",
        "D": "Bronchiectasis"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Idiopathic pulmonary fibrosis Explanation: Idiopathic pulmonary fibrosis (IPF) is a common indication for single lung transplantation , as it primarily affects the lungs without the risk of cross-contamination seen in diseases like cystic fibrosis (Option A) or bronchiectasis (Option D) , which often require double lung transplantation. Pulmonary Arterial Hypertension (Option B) is generally managed with double lung or heart-lung transplantation Types of Transplant: Indications: Diseases Type of transplant Cystic fibrosis Bilateral and living related (or cadaveric lobar transplants in small highly selected recipients in experienced centers) Interstitial (fibrotic) lung disease Bilateral or single (but associated with poorer long-term survival) Emphysema/COPD Bilateral or single (but associated with poorer long-term survival) Pulmonary hypertension Bilateral (or rarely combined heart-lung transplantation especially if associated with congenital heart disease) Complications of lung transplantation Primary graft dysfunction Bleeding Parenchymal and pleural infection Bronchial anastomotic dehiscence or stenosis Vascular anastomotic stenosis or kinking Rejection - acute or chronic (chronic lung allograft dysfunction) [CLAD] Infection - bacterial, viral or fungal - donor or recipient acquired Phrenic nerve palsy Gastro-oesophageal reflux",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 3,
      "question": "A 55 y/o male who underwent heart transplantation 10 years ago presents with exertional dyspnea and fatigue for a few weeks. His initial post-transplant course was uneventful, and he has been compliant with his immunosuppressive regimen. What is the most common cause of late mortality in heart transplant recipients that should be considered in this patient?",
      "options": {
        "A": "Graft rejection",
        "B": "Infection",
        "C": "Cardiac allograft vasculopathy (CAV)",
        "D": "Renal failure"
      },
      "correct_answer": "C",
      "explanation": "(CAV): The most common cause of late mortality in heart transplant recipients is cardiac allograft vasculopathy (CAV). It is a form of chronic rejection characterized by diffuse, progressive narrowing of the coronary arteries in the transplanted heart, leading to ischemic heart disease. CAV often presents with nonspecific symptoms like exertional dyspnea or fatigue due to the denervation of the transplanted heart , which can mask typical angina. Complications of Heart Transplantation: S.no. Complications Causes 1. Primary Graft Dysfunction (PGD) (Occurs in about 10% of cases, leading to low cardiac output and biventricular failure.) Associated with Ischemia-reperfusion injury Older donor/recipient age Prolonged ischemic time Donor-recipient size mismatch 2. Right Ventricular Failure Can occur due to Prolonged ischemic time. Elevated pulmonary vascular resistance. Volume overload. Donor size mismatch. 3. Rejection (Option A) Hyperacute Rejection: Rare, due to blood type cross-matching. Acute Cellular Rejection: T-cell mediated, occurring in 20-40% of patients, especially in the first 12 months. Antibody-Mediated Rejection (AMR): Occurs in 10-20% of patients with a mortality rate of 8%. 4. Chronic Allograft Vasculopathy (CAV) (Option C) Leading cause of late mortality Involves diffuse coronary arterial intima thickening. Patients often present with heart failure due to denervation of the heart, lacking ischemic chest pain. 5. Infection (Option B) Increased risk due to lifelong immunosuppression. 6. Malignancy Immunosuppression-related, with higher incidence in long-term survivors. 7. Renal Dysfunction (Option D) Often due to nephrotoxic effects of calcineurin inhibitors used in immunosuppression. 8. Diabetes and Hyperlipidemia Resulting from long-term steroid and immunosuppressant use Reference: Bailey and Love’s Short Practice of Surgery, 28th Edition, Page 1640.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 4,
      "question": "A 45-year-old male with end-stage heart failure secondary to ischemic cardiomyopathy is being evaluated for orthotopic heart transplantation. After confirming the indications for transplantation, the surgical team begins the procedure. Which of the following represents the correct sequence of anastomoses typically performed? → Left atrium → Aorta → Right atrium → Right atrium → Pulmonary artery → Aorta → Pulmonary artery → Left atrium → Right atrium → Aorta → Pulmonary artery → Left atrium",
      "options": {
        "A": "Pulmonary artery",
        "B": "Left atrium",
        "C": "Aorta",
        "D": "Right atrium"
      },
      "correct_answer": "B",
      "explanation": "→ Right atrium → Pulmonary artery → Aorta → Right atrium → Pulmonary artery → Aorta Explanation: The Sequence of Anastomosis In Heart transplantation: Left Atrium: The first anastomosis is performed on the left atrium to restore pulmonary venous return, which is vital for maintaining adequate oxygenated blood flow from the lungs to the heart. Right Atrium: The next step is the anastomosis of the right atrium, establishing venous return from the body through the superior and inferior vena cavae. Pulmonary Artery: This is followed by the pulmonary artery anastomosis to allow deoxygenated blood to flow from the right ventricle to the lungs for oxygenation. Aorta: Finally, the aorta is connected to facilitate the distribution of oxygenated blood from the left ventricle to the systemic circulation. This sequence ensures a stepwise reestablishment of circulation, reducing ischemic time for the donor heart and allowing for efficient restoration of heart function post-transplantation. Indications for Heart Transplantation: 1. End-stage heart failure unresponsive to maximal medical therapy. 2. Multiple hospitalizations due to decompensated heart failure. 3. Severe reduction in ejection fraction (EF < 20%) indicating poor heart function. Reference: Bailey and Love’s Short Practice of Surgery, 28th Edition, Page 1639",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 5,
      "question": "In isolated intestine transplantation, the venous outflow from the allograft is typically established by anastomosis of which of the following?",
      "options": {
        "A": "Donor SMV to the recipient superior vena cava",
        "B": "Donor SMV to the recipient portal vein or inferior vena cava",
        "C": "Donor SMA to the recipient portal vein",
        "D": "Donor SMV to the recipient splenic vein"
      },
      "correct_answer": "B",
      "explanation": "outflow in isolated intestine transplantation is typically established by anastomosis of the donor superior mesenteric vein (SMV) to either the recipient's portal vein or inferior vena cava . Isolated Intestine Allografts: Typically include the entire jejunum and ileum with the associated vasculature (SMA and SMV). Donor Operation: Vascular Transection: Varies depending on whether the pancreas is allocated separately. Neonatal Donor/Isolated Pancreas Not Allocated: SMA divided at the aorta. Portal vein is divided at the superior border of the pancreas for maximum vessel length. Adult/Older Pediatric Donors: SMA and SMV are divided at the mesenteric root at the inferior border of the pancreas to allow use of liver and pancreas for other recipients. Bowel Transection: Jejunum divided distal to the ligament of Treitz. Ileum transected proximal to the ileocecal valve. Recipient Operation: Arterial Inflow: Established by direct anastomosis of the donor SMA to the recipient infrarenal aorta or with a donor arterial conduit. Venous Outflow: Anastomosis of the donor SMV to the recipient portal vein or inferior vena cava, with or without a donor venous conduit. Bowel Continuity: Proximal duodeno-jejunostomy . Distal Ileostomy: Created for routine monitoring of the graft.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 6,
      "question": "A transplant team is evaluating potential cadaveric donors for a small bowel transplant. Criteria for donor selection include compatible blood type, size of the donor relative to the recipient, and viral serologic testing. Which of the following is NOT a criterion for donor selection in small bowel transplantation?",
      "options": {
        "A": "Blood type compatibility",
        "B": "Donor body weight 50% to 75% of the recipient’s weight",
        "C": "Maximum cold ischemia time of 10 to 12 hours",
        "D": "Donor's minimal vasopressor requirement"
      },
      "correct_answer": "C",
      "explanation": "ischemia time for small bowel transplantation is 6 to 8 hours . A cold ischemia time of 10 to 12 hours exceeds the recommended duration and may lead to complications such as loss of mucosal integrity, bacterial translocation, or intestinal perforation. Criteria for donor selection in small bowel transplantation: 1. Blood Type: Donor selection is based on compatible blood type. ( Option A ) 2. Size Compatibility: Size is crucial due to loss of abdominal domain in recipients. Ideal donor body weight: 50% to 75% of the recipient's weight. ( Option B ) 3. Abdominal Surgical History: Extensive abdominal surgical history in the donor may preclude procurement. 4. Cold Ischemia Time: Intestinal allografts are sensitive to cold ischemia due to their highly vascularized and metabolically active mucosa. Maximum cold ischemia time advised: 6 to 8 hours. Hence, Donors should be hemodynamically stable, require minimal vasopressor support, and be geographically close to the transplant center. ( Option D ) 5. Viral Serologic Testing: Testing for Epstein-Barr virus (EBV) and cytomegalovirus (CMV) is crucial to avoid risks such as post-transplant lymphoproliferative disorder (PTLD) and severe enteritis. Reference: Sabiston Textbook of Surgery, 21st Edition, Page 646",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 7,
      "question": "A 50-year-old female with a history of type 1 diabetes mellitus presents with recurrent severe hypoglycemia with decreased awareness. He is scheduled for islet cell transplantation. Which immunosuppressive regimen is most commonly used to prevent immune rejection of the transplanted islet cells?",
      "options": {
        "A": "Cyclosporine + azathioprine + prednisolone",
        "B": "Methotrexate + mycophenolate mofetil + hydrocortisone",
        "C": "Cyclophosphamide + etanercept + rituximab",
        "D": "Daclizumab + sirolimus + tacrolimus"
      },
      "correct_answer": "D",
      "explanation": "therapy with Daclizumab + Maintenance therapy with sirolimus and tacrolimus is given for immunosuppression after islet cell transplantation. Indications for islet cell transplantation: Recurrent severe hypoglycemic episodes without recognizing them Procedure: Islet cells are infused into the portal vein under image guidance. Compilations: Portal vein thrombosis: Complete loss of the graft Bleeding, mycotic aneurysms, infections, pancreatic fistulas, bile leak, and pancreatitis. Immunosuppression: Lifelong immunosuppression is required Edmonton regimen: Induction therapy with Daclizumab + Maintenance therapy with sirolimus and tacrolimus is given for immunosuppression after islet cell transplantation. For insulin independence, 8000 to 10000 islet cells/kg of the recipient’s body weight should be transferred. Hence, for one transplantation four donors are needed. Cyclosporine + azathioprine + prednisolone (Option A): Traditional in solid organ transplants, but less favoured for islet transplantation due to beta-cell toxicity and less specific immunomodulation. Methotrexate + mycophenolate mofetil + hydrocortisone (Option B): Not standard for islet transplantation. Methotrexate is not typically used in this context. Cyclophosphamide + etanercept + rituximab (Option C): More commonly used in autoimmune conditions or bone marrow transplant conditioning , not routine for islet cell transplant. Reference: ttps://www.ncbi.nlm.nih.gov/books/NBK562272/ Sabiston Textbook of Surgery, 21st Edition, Page 640, 641 https://pubmed.ncbi.nlm.nih.gov/17005949/#:~:text=Conclusions%3A%20Islet%20transplantation%20with%2 0the,independence%20is%20usually%20not%20sustainable",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 8,
      "question": "A 45-year-old male with a history of type 1 diabetes mellitus undergoes a pancreas transplantation. On postoperative day 3, he develops sudden-onset severe abdominal pain, and doppler ultrasound reveals no blood flow to the pancreas graft. What is the most common cause of pancreatic graft failure in this scenario?",
      "options": {
        "A": "Vascular thrombosis",
        "B": "Anastomotic leak",
        "C": "Pancreatitis",
        "D": "Bleeding"
      },
      "correct_answer": "A",
      "explanation": "non-immunologic cause of pancreatic graft failure. Complications of pancreatic transplantation: Leak: (Option B) Enteric leak - needs surgical intervention Bladder leak - small leak is managed with foley’s catheter Vascular Complications: Bleeding : (Option D) Immediate posttransplantation bleeding: From the pancreatic parenchyma Delayed gastrointestinal bleeding: From the en enteric anastomosis Late gastrointestinal bleeding: CMV infection, duodenal ulcers of the duodenal stump from ischemia, pseudoaneurysm development. Thrombosis: Most common nonimmunologic cause of pancreas transplant failure (Option A) Majority of graft thrombosis occur early Emergent exploratory laparotomy with transplant pancreatectomy is necessary in most cases. Infection Pancreatitis: (Option C) Early pancreatitis is likely due to reperfusion injury to the graft Most cases are self-limited Bowel obstruction Reference: Sabiston Textbook of surgery, 21st Edition, Page 639, 640",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 9,
      "question": "Which of the following statements is/are true regarding pancreas transplantation? Type-2 DM with clear c-peptide deficiency is not an indication for pancreas transplantation. End-to-end anastomosis is done between the internal iliac artery and splenic artery Systemic venous drainage is preferred over portal venous drainage Enteric drainage of endocrine secretion is preferred",
      "options": {
        "A": "Only 2",
        "B": "1, 2, and 4",
        "C": "2 and 3",
        "D": "All of the above"
      },
      "correct_answer": "C",
      "explanation": "c-peptide deficiency Simultaneous pancreas and kidney transplantation(SPK) Insulin requirements of less than <1 unit/kg body weight in 24 hours Type 1 diabetes with end-stage renal failure requiring dialysis or dialysis predicted within 6 months (GFR <20 mL/min) Procedure of pancreas transplantation: Intraperitoneal or extraperitoneal procedure The exocrine drainage of the pancreas is managed by connection to the small intestine or urinary bladder Minimal handling of the pancreas during the procurement is needed Iliac artery is used as a Y graft: End-to-end anastomosis is done between Internal iliac and splenic artery External iliac and superior mesenteric artery A graft is placed on the right side to prevent undue stretching of the venous anastomosis Systemic venous drainage: Portal vein is anastomosed to the external iliac vein or common iliac vein or distal part of IVC Portal drainage: Donor portal vein is anastomosed to recipient's proximal superior mesenteric vein Enteric drainage of the exocrine pancreas: Duodenal stump of graft is anastomosed to the recipients mid jejunum Orientation of the duodenum can be superior, or inferior Bladder drainage of the exocrine pancreas: 4-5cm cystostomy is made on the anterior dome of the bladder Orientation of the duodenum is always inferior Advantage of bladder drainage: Allows monitoring of urinary amylase Note: Systemic venous drainage is preferred over portal venous drainage Enteric drainage is preferred over bladder drainage Usually transplantation is done intraperitoneally with the PV anastomosed to the IVC and the Y-graft anastomosed to the CIA",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 10,
      "question": "Which of the following statements is NOT true regarding contraindications and complications of renal transplantation?",
      "options": {
        "A": "Renal vein thrombosis post-surgery is managed conservatively with anticoagulants",
        "B": "Active IV drug abuse is a contraindication for the transplant",
        "C": "Lymphocele can cause ureteric obstruction",
        "D": "Renal artery stenosis post-transplant is best treated by angioplasty"
      },
      "correct_answer": "A",
      "explanation": "anticoagulants Complications of renal transplantation: The most common complication in living donors is urinary retention and ileus. In recipient: Hemorrhage Renal artery thrombosis (<1%) and Renal vein thrombosis (1–5%): (Option A) Diagnosis- doppler Urgent surgical exploration is needed as it is an emergency. In most cases, a transplant nephrectomy is needed. Renal artery stenosis: Late complication mostly Decrease in renal function Hypertension Best treated by angioplasty. (Option D) Urinary leak : Commonly due to ischaemic necrosis of the distal ureter Ureteric obstruction: Short strictures- balloon dilatation and double-J stent placement. Long, tight strictures- reimplantation of donor ureter into the bladder Lymphocele: (Option C) Usually asymptomatic Large lymphocele- ureteric obstruction Edema of ipsilateral led Treatment- USG-guided percutaneous drainage or drainage into the peritoneal cavity. Acute renal allograft dysfunction: Acute rejection (antibody-mediated or cell-mediated) Calcineurin inhibitor toxicity Dehydration Urinary tract infection or pyelonephritis Sepsis Renal vein or renal artery thrombosis Ureteric obstruction or urine leak Long-term allograft dysfunction: Immunological and non-immunological causes. Contraindications of renal transplant: Absolute Active malignant disease Active infection Unreconstructable peripheral vascular disease Severe cardiac or pulmonary disease Active intravenous drug abuse (Option B) Significant psychosocial barriers Relative Limited life expectancy History of nonadherence to medication History of noncompliance with dialysis Financial barriers Renal disease with a high recurrence rate Morbid obesity Reference: Bailey and Love’s Short Practice of Surgery, 28th edition, Page 1605-1607 Sabiston Textbook of Surgery, 21st edition, Page 628",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 11,
      "question": "A 45-year-old male with end-stage renal disease due to polycystic kidney disease is scheduled for a renal transplant, with his brother serving as the donor. During the transplant procedure, where is the donor kidney typically placed, and to which vessel is its renal artery anastomosed?",
      "options": {
        "A": "Right hypochondrium and aorta",
        "B": "Left hypochondrium and external iliac artery",
        "C": "Iliac fossa and Internal iliac artery",
        "D": "Lumbar region and Inferior vena cava"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Iliac fossa and Internal iliac artery Explanation: In living donors, the donor renal artery is anastomosed to the internal iliac artery and the renal graft is placed in the iliac fossa. Indications for renal transplantation: End-stage renal disease caused by: G lomerulonephritis D iabetic nephropathy H ypertensive nephrosclerosis R enal vascular disease P olycystic Kidney disease/Chronic P yelonephritis O bstructive uropathy S LE A nalgesic nephropathy M etabolic disease (oxalosis, amyloid) Mnemonic: GD for HR POSt at 4 AM Renal transplant procedure: Preparation of the donor kidney: inspected and examined. The left kidney is preferred as it has a longer left renal vein. Operative technique: The donor kidney is transplanted into one of the iliac fossae (Option C) (retroperitoneal location) leaving the native kidney in situ. Hence, a total of 3 kidneys in the recipient. The donor renal vein is anastomosed end to side to the external or common iliac vein. In a cadaveric donor, the renal artery is anastomosed end to side to the external or common iliac artery. In live donors, end-to-end anastomosis to the divided internal iliac artery is used more commonly due to the lack of an aortic patch (Carrel’s patch) . Ureter implantation: Ureter length is kept short to avoid distal ischemia Anastomosis to the bladder is achieved by the Lich-gregoir technique (preferred): Implantation by direct mucosa to mucosa anastomosis to a small cystotomy.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 12,
      "question": "Which of the following parameters is NOT included in the MELD (Model for End-Stage Liver Disease) score?",
      "options": {
        "A": "Bilirubin",
        "B": "Creatinine",
        "C": "International Normalized Ratio (INR)",
        "D": "Albumin"
      },
      "correct_answer": "D",
      "explanation": "End-Stage Liver Disease) and not the MELD (Model for End-Stage Liver Disease) score. MELD (Model for End-Stage Liver Disease) score: Predicts prognosis in chronic liver disease It was developed to predict 3-month mortality in patients after TIPSS (transjugular portosystemic shunt) Used in UNOS (United Nations Organ Sharing Network) to determine priority for liver transplantation. Most patients with low MELD scores (less than 15) do not benefit from transplantation Score: 6 - 40 Components: C reatinine (Option B) B ilirubin (Option A) I NR (Option C) PELD (Pediatric End-Stage Liver Disease) Score: Used to determine priority for children awaiting liver transplantation Components: N utrition A ge B ilirubin I NR A lbumin (Option D) Reference: https://pubmed.ncbi.nlm.nih.gov/12151728/ Bailey & Love's, Short Practice of Surgery, 28th Edition, Page 1620 Sabiston Textbook of Surgery, The Biological Basis of Modern Surgical Practice, 21st Edition, Page 618, 619",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 13,
      "question": "A 55-year-old patient with end-stage liver disease receives a liver from a donor with familial amyloid polyneuropathy (FAP) as part of a domino liver transplantation. Which of the following statements is incorrect? malignancy recurrence.",
      "options": {
        "A": "It can use a liver from a patient with familial amyloid polyneuropathy (FAP).",
        "B": "FAP symptoms appear immediately after transplantation.",
        "C": "If the recipient later develops FAP symptoms, they can undergo a retransplantation without risk of",
        "D": "The recipient is less likely to develop or be significantly affected by the metabolic syndrome"
      },
      "correct_answer": "B",
      "explanation": "develop 10-20 years after transplantation, not immediately. Domino Liver Transplantation Definition : Transplanting a liver from a patient with a metabolic disease into a patient with end-stage liver disease. Rationale : The donor’s liver has a normal structure and function but would eventually cause systemic disease in the donor. The recipient is less likely to develop or be significantly affected by the metabolic syndrome. (Option D) Example : Liver from a patient with familial amyloid polyneuropathy (FAP) can be transplanted into a patient with end-stage liver disease, even if the recipient is outside transplant criteria due to liver malignancy. Symptoms of FAP may develop in 10-20 years. (Option B) Key Benefit : If the recipient does not develop malignancy recurrence and later becomes symptomatic from the metabolic disease, they can receive a retransplant without the risk of malignancy recurrence. (Option C) Suitable Metabolic Diseases : Familial amyloid polyneuropathy (FAP) (Option A) Maple syrup urine disease Familial hypercholesterolemia Mechanism : These diseases result from aberrant or deficient protein production in the liver. They are curable by an orthotopic liver transplant. Reference: Bailey & Love’s Short Practice of surgery, 28th Edition, Page 1615",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 14,
      "question": "Which of the following best describes the definition of a \"deceased person\" according to the Transplantation of Human Organs Act?",
      "options": {
        "A": "A person who has been unconscious for more than 24 hours.",
        "B": "A person who has a permanent cessation of all evidence of life.",
        "C": "A person who has been declared clinically dead but with potential for revival.",
        "D": "A person who has undergone a major surgery with no sign of life for 6 hours."
      },
      "correct_answer": "B",
      "explanation": "to the Act, a \"deceased person\" is defined as one who has experienced a permanent cessation of all signs of life , which is crucial for determining organ donation eligibility. This definition ensures that the donor is truly deceased and prevents confusion with conditions like clinical death or severe unconsciousness. Transplantation of Human Organs Act, India (1994) Purpose : Regulate organ transplantation and ensure ethical organ donation practices, particularly for deceased donors. Evolution of the Act Year Amendment Focus 2008 Improved framework for deceased organ donation 2011 Updated to reflect advancements in medical and ethical standards Deceased Person Definition : Permanent cessation of all signs of life is necessary to qualify for organ donation. (Option B) Objectives Promote Organ Donation : Structured approach to increase available organs. Ensure Ethical Practices : Prevent illegal organ trade; adhere to ethical standards. Legal Framework : Provides guidelines for registering transplant centers and authorizing procedures. Reference: https://pubmed.ncbi.nlm.nih.gov/22728294/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067489/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 15,
      "question": "A 40-year-old male with end-stage liver disease due to chronic hepatitis C is being evaluated for a liver transplant. During the evaluation, it was noted that his 38-year-old sister is willing to donate a portion of her liver. Which of the following liver transplant options is most appropriate for this patient?",
      "options": {
        "A": "Deceased Donor Liver Transplantation (DDLT)",
        "B": "Domino Liver Transplantation",
        "C": "Living Donor Liver Transplantation (LDLT)",
        "D": "Split Liver Transplantation"
      },
      "correct_answer": "C",
      "explanation": "Transplantation (LDLT) involves transplanting a portion of the liver from a living donor, making it an appropriate option when a suitable living donor, such as the patient's sister, is available. Liver Transplant Types Deceased Donor Liver Transplantation (DDLT): (Option A) Source: Donors after brain death (DBD) or circulatory death (DCD). Note: DCD livers are at higher risk of damage but increase organ availability. Living Donor Liver Transplantation (LDLT): (Option C) Source: A portion of the liver from a living donor. Application: Common where deceased donor organs are scarce. Split Liver Transplantation: (Option D) Procedure: Divide a deceased donor's liver into two parts. Recipients: Pediatric (left lateral segment) and adult (extended right lobe). Reduced-size Liver Transplantation: Procedure: Resect a portion of a full-size liver to fit a smaller recipient. Use: Urgent cases, no additional graft generated. Auxiliary Liver Transplantation: Procedure: Graft implanted while preserving native liver (e.g., APOLT). Application: Bridge to native liver regeneration in acute liver failure. Domino Liver Transplantation: (Option B) Source: Donor with metabolic liver disease. Note: Recipients may develop metabolic syndrome later. Paired-exchange Programs: Method: Incompatible donor-recipient pairs exchange livers for compatibility. Indications for Liver Transplantation: Acute Liver Failure (ALF) Chronic Liver Disease (CLD) Hepatic Malignancy Metabolic Liver Diseases Contraindications for Liver Transplantation Active Systemic Sepsis/Infection Advanced Age Uncontrolled comorbidities Active substance abuse Malignancy- Excludes transplantation if within the past five years, except for select liver cancers. Reference: Bailey & Love’s Short Practice of Surgery, 28th Edition, Page 1596, 1602, 1608, 1609, 1612, 1613, 1614, 1615, 1637.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 16,
      "question": "Which of the following methods is currently considered the gold standard for preserving the pancreas before transplantation?",
      "options": {
        "A": "Hypothermic machine perfusion (HMP)",
        "B": "Normothermic machine perfusion (NMP)",
        "C": "Static cold storage (SCS) with University of Wisconsin (UW) solution",
        "D": "Normothermic regional perfusion (NRP)"
      },
      "correct_answer": "C",
      "explanation": "Static cold storage (SCS) with University of Wisconsin (UW) solution: This is the most commonly used and considered the gold standard for organ preservation, especially for the pancreas. The UW solution contains hydroxyethyl starch (HES), which is crucial for reducing metabolic activity and preserving the pancreas during cold storage. Organ Preservation in Transplantation Goal: Maintain organ viability between retrieval and transplantation. Types of Ischemia: Warm Ischemia: Lack of blood flow at body temperature. Cold Ischemia: Lack of blood flow while the organ is cooled. Pancreas Sensitivity: Highly vulnerable to both warm and cold ischemia. Methods of Organ Preservation Method Description Advantages/Limitations Static Cold Storage (SCS) (Option C) Cooling the organ to 4°C with a preservation solution to reduce metabolism. The most common method. Uses the University of Wisconsin (UW) solution UW solution contains hydroxyethyl starch (HES), crucial for pancreas preservation. Hypothermic Machine Perfusion (HMP) (Option A) Continuously pumps cooled preservation solution through the organ's vasculature. Promising in experimental settings. Normothermic Machine Perfusion (NMP) (Option B) Circulates warm, oxygenated, red blood cell-based perfusate through the organ. Creates a physiological environment ex vivo . Used in other organs (heart, lung, liver, kidney). Less successful for the pancreas due to organ injury from high autolytic enzyme concentrations. Normothermic Regional Perfusion (NRP) (Option D) Warm, oxygenated blood is pumped back through abdominal organs after circulatory arrest. Beneficial for liver preservation. Efficacy for pancreas transplantation remains inconclusive. Ex Vivo Lung Perfusion (EVLP) Technique: Ventilation and perfusion of donor lungs with a solution ex vivo . Purpose: Reconditioning and evaluation of lungs before transplantation. Potential Benefits: May increase the number of viable organs for transplant and enable future therapeutic interventions like gene therapy. Reference: Bailey & Love’s Short Practice of Surgery, 28th Edition, Page 1598, 1619, 1623, 1624, 1643.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 17,
      "question": "A 45-year-old male is declared legally dead due to irreversible brainstem function loss following a severe head injury. He is considered for organ donation. Which of the following statements is true regarding Donation After Brainstem Death (DBD)?",
      "options": {
        "A": "In DBD complications like graft dysfunction, especially with the liver and pancreas, are expected.",
        "B": "A 5-minute \"no-touch\" period is observed in the case of DBD.",
        "C": "In DBD, organs are perfused with oxygenated blood at the time of procurement.",
        "D": "Warm ischemia is seen in DBD."
      },
      "correct_answer": "C",
      "explanation": "retrieval, generally ensuring better viability and outcomes. Differences Between DBD and DCD Donors Feature DBD (Donation After Brainstem Death) DCD (Donation After Circulatory Death) Terminology Heart-beating donors Asystolic or Non-heart-beating donors Legal Death Criteria Irreversible brainstem function loss Irreversible cessation of circulatory function Organ Condition Perfused with oxygenated blood at the time of procurement (Option C) Warm but not perfused with oxygenated blood; risk of warm ischemia (Option D) Procedure Timing Organ retrieval after brainstem death declaration Controlled DCD: Retrieval after a 5-minute \"no-touch\" period post-arrest. (Option B) Uncontrolled DCD : Retrieval following failed resuscitation in the ICU or ED, with potential kidney recovery after ischemia. Viability & Outcomes Generally good, with organs in better condition due to oxygenation Variable quality; higher risk of complications like graft dysfunction. Outcomes can improve with machine perfusion and careful organ selection. (Option A) Reference: Bailey & Love’s Short Practice of Surgery, 28th Edition, Page 1595, 1596, 1612, 1613.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 18,
      "question": "A 52-year-old female who received a multi-visceral transplant presents with unexplained fever, night sweats, and significant weight loss. Her laboratory results show persistent Epstein–Barr virus (EBV) viremia. Which of the following transplant recipients is at the highest risk of developing post-transplant lymphoproliferative disorder (PTLD)?",
      "options": {
        "A": "Kidney transplant recipient",
        "B": "Liver transplant recipient",
        "C": "Intestinal transplant recipient",
        "D": "Heart transplant recipient"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Intestinal transplant recipient Explanation: Intestinal transplant recipients have the highest risk of developing PTLD, with an incidence of up to 17%, due to the high level of immunosuppression and the large amount of lymphoid tissue in the graft. Post-Transplant Lymphoproliferative Disorder (PTLD) Complication of Immunosuppression: PTLD can develop as a complication following organ transplantation due to immunosuppression. Higher Incidence in Intestinal Transplants: PTLD incidence is notably higher in intestinal transplant recipients, with rates reported up to 17%. Reason for Higher Incidence: Increased immunosuppression and the presence of extensive lymphoid tissue in intestinal grafts contribute to this higher risk. Symptoms and Diagnosis: Persistent Epstein–Barr virus (EBV) viremia or B symptoms (night sweats, unexplained fevers, weight loss) should prompt consideration of PTLD. Treatment Approach: First-Line Treatment: Rituximab and careful reduction of immunosuppression. Caution Required: Especially in multi-visceral/intestinal transplants to avoid rejection. Reference: Bailey & Love’s Short Practice of Surgery, 28th edition, Page 1635",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 19,
      "question": "In transplant recipients, which of the following is the most common cause of viral infection within the first 6 months post-transplant?",
      "options": {
        "A": "Herpes Simplex Virus (HSV)",
        "B": "Cytomegalovirus (CMV)",
        "C": "Epstein-Barr Virus (EBV)",
        "D": "BK Virus"
      },
      "correct_answer": "B",
      "explanation": "viral infection in transplant recipients within the first 6 months after transplantation. CMV often reactivates in immunosuppressed patients, leading to systemic and organ-specific complications. CMV is one of the most frequent opportunistic infections after organ transplantation. Sources of Infection: Reactivation: Often due to reactivation of latent CMV in the recipient. Primary Infection: This can occur if the donor is CMV-positive and the recipient is CMV-negative. Clinical Manifestations: Typically manifests within the first 6 months (30-50 days) post-transplant. Systemic Symptoms: Fever, fatigue, and malaise. Organ-Specific Involvement: Can affect various organs including the lungs (pneumonitis), gastrointestinal tract(colitis), liver(hepatitis), and eyes(retinitis). Risk Factors: Higher levels of immunosuppressive therapy increase the risk. Diagnosis: Confirmatory test – Invasive CMV infection with histological evidence or positive CMV culture from deep tissue specimen Treatment: IV Ganciclovir (main treatment) Also used for chemoprophylaxis Reference: https://www.ncbi.nlm.nih.gov/books/NBK459185/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 20,
      "question": "Which intervention has been shown to reduce the risk of graft loss in kidney transplant recipients with BK virus nephropathy?",
      "options": {
        "A": "Increasing the dosage of calcineurin inhibitors",
        "B": "Administering antiviral therapy as a first-line treatment",
        "C": "Timely reduction of immunosuppressive therapy",
        "D": "Routine use of corticosteroids"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Timely reduction of immunosuppressive therapy Explanation: Timely reduction of immunosuppressive therapy has been proven to significantly reduce graft loss in kidney transplant recipients with BK virus nephropathy, lowering the risk from 90% to 10%. BK Virus: Belongs to the Polyomavirus family. Infection in Transplant Recipients : Reactivation : Can reactivate in immunocompromised patients, particularly in kidney transplant recipients. Timing : 1-4 months after transplantation. Clinical Manifestations : BK Virus Nephropathy (BKVN) : Can lead to kidney injury, presenting as acute or chronic renal dysfunction. Associated Conditions : Ureteric Strictures : Blockage or narrowing of the ureters. Nephropathy : Renal dysfunction due to viral infection. Generalized Vasculopathy : Damage to blood vessels throughout the body. Diagnosis : PCR Testing- Detection of BK virus DNA in blood and urine. Increased levels of replication are predictive of pathology in renal transplantation. Management : Reduce Immunosuppression : Early and timely reduction of immunosuppressive drugs can significantly reduce the risk of graft loss, from 90% to 10%. Regular Monitoring : Frequent monitoring of BK virus levels in urine and blood, alongside kidney function tests. Prevention : Screening : Regularly monitor BK virus levels in transplant recipients. Early Intervention : Adjust immunosuppressive therapy promptly upon detection of BK virus reactivation to prevent nephropathy and associated complications. Increasing the dosage of calcineurin inhibitors ( Option A): Increasing the dosage of calcineurin inhibitors can exacerbate BK virus nephropathy by further suppressing the immune system. Administering antiviral therapy as a first-line treatment (Option B): While antiviral therapy may be used in severe cases, the primary strategy for reducing graft loss is to manage immunosuppression. Routine use of corticosteroids (Option D): Routine use of corticosteroids is not specific to managing BK virus nephropathy and can contribute to further complications. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084638/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 21,
      "question": "Which of the following is the most common malignancy in transplant recipients?",
      "options": {
        "A": "Kaposi Sarcoma",
        "B": "Post-transplant lymphoproliferative Disorder (PTLD)",
        "C": "Squamous Cell Carcinoma",
        "D": "Cytomegalovirus-Associated Tumors"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Squamous Cell Carcinoma Explanation: Squamous Cell Carcinoma is the most common malignancy in transplant recipients. Due to the long-term immunosuppression required to prevent organ rejection, transplant recipients have an increased risk of developing skin cancer, with squamous cell carcinoma being particularly prevalent. Infections High Risk of Opportunistic Infections : Primarily caused by viruses. Source of Infections : More commonly recipient-derived than donor-derived. Bacterial Infections : Most prevalent within the first month post-transplant. Viral Infections : Peak within the first 6 months post-transplantation. Most common- Cytomegalovirus (CMV) Preventative Measures : High-risk patients require chemoprophylaxis. Vaccination : Pre-transplant immunization is recommended to protect against community-acquired infections. Malignancy Most Common Cancer : Skin cancer, specifically squamous cell carcinoma, is the most frequent malignancy in transplant recipients. Increased Cancer Risks : PTLD : Post-transplant lymphoproliferative disorder. Kaposi Sarcoma : Increased incidence among transplant recipients. Non-Immune Side Effects Hypertension and Chronic Allograft Neuropathy : Typically associated with calcineurin inhibitors like Cyclosporine and Tacrolimus. New-Onset Diabetes Mellitus : Often caused by steroids or Tacrolimus post-transplantation. Elevated Risk of : Hyperlipidemia Anemia Cardiovascular Disease- leading cause of death among transplant survivors. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152453/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 22,
      "question": "Which of the following drugs works by inhibiting T-cell activation through the blockage of calcineurin, ultimately reducing IL-2 production?",
      "options": {
        "A": "Azathioprine",
        "B": "Prednisone",
        "C": "Tacrolimus",
        "D": "Sirolimus"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Tacrolimus Explanation: Tacrolimus is a calcineurin inhibitor that works by blocking the enzyme calcineurin, leading to a reduction in IL-2 production and subsequent T-cell activation. Class Examples Mechanism of Action Calcineurin Inhibitors Cyclosporine, Tacrolimus Inhibit T-cell activation by blocking calcineurin, reducing IL-2 production Antimetabolites Azathioprine (Option A), Mycophenolate mofetil Inhibit nucleotide synthesis, suppressing lymphocyte proliferation mTOR Inhibitors Sirolimus (Option D) , Everolimus Inhibit the mTOR pathway, blocking cell cycle progression in T-cells Corticosteroids Prednisone (Option B), Methylprednisolone Broad anti-inflammatory effects; reduce cytokine production Monoclonal Antibodies Basiliximab, Rituximab, Belatacept Target specific immune cells or cytokines to inhibit immune responses Anti-thymocyte Globulin (ATG) - Polyclonal antibodies that deplete T-cells, reducing immune response Reference: Bailey and Love’s Short Practice of Surgery, 27th Edition, Page 601, 602 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987166/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 23,
      "question": "Which type of graft involves tissue transplantation between genetically identical individuals, such as identical twins?",
      "options": {
        "A": "Autograft",
        "B": "Allograft",
        "C": "Isograft",
        "D": "Xenograft"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Isograft Explanation: An isograft involves tissue transplantation between genetically identical individuals, such as identical twins. Graft Type Source Advantages Disadvantages Autograft (Option A) Tissue from one site to another on the same individual No risk of immune rejection; high success rate Requires a donor site, additional morbidity Allograft (Option B ) Tissue from another individual of the same species Availability of larger tissue amounts Risk of immune rejection; needs immunosuppression Xenograft (Option D) Tissue from a different species (e.g., pig to human) Readily available; used as temporary grafts High risk of immune rejection; often temporary Isograft (Option C) Tissue between genetically identical individuals No risk of immune rejection due to genetic identity Limited availability; specific to identical twins Concordant Xenograft: Xenograft between closely related species. Compatibility: Better immune compatibility; lower risk of hyperacute rejection. Example: Primate to human (e.g., baboon to human). Discordant Xenograft: Xenograft between distantly related species. Compatibility: Poor immune compatibility; high risk of hyperacute rejection. Example: Pig to human. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624478/ https://www.ncbi.nlm.nih.gov/books/NBK45531/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 24,
      "question": "A 45-year-old patient requires a kidney transplant. Which statement about HLA matching is most accurate for this transplant? mismatches at the HLA-DR locus.",
      "options": {
        "A": "Mismatches at the HLA-B locus have a more significant impact on transplant outcomes than",
        "B": "HLA typing is typically performed using DNA sequencing to assess compatibility.",
        "C": "HLA Class I molecules are categorized into HLA-DP, HLA-DQ, and HLA-DR.",
        "D": "Tissue typing in transplantation includes HLA-B, HLA-C, and HLA-DP loci."
      },
      "correct_answer": "B",
      "explanation": "compatibility. Transplantation Definition: HLA (Human Leukocyte Antigen) matching is essential in organ transplantation to reduce the risk of graft rejection. HLA molecules, also known as MHC (Major Histocompatibility Complex) antigens, help the immune system distinguish between self and foreign tissues. HLA Typing: Performed using DNA sequencing to assess compatibility between donor and recipient. (Option B) Aims to minimize mismatches at key HLA genes, though perfect matches are rare due to HLA polymorphism. HLA Classes Class HLA Molecules Characteristics Class I (Option C) HLA-A, HLA-B, HLA-C Present on most cells, involved in immune response. Class II HLA-DP, HLA-DQ, HLA-DR Found on antigen-presenting cells, critical for immune recognition. Significance of HLA Antigens HLA-DR : Particularly important in kidney transplantation. Impact of Mismatches : DR locus mismatches have the greatest impact on transplant outcomes. (Option A) B locus mismatches are more significant than A locus mismatches. Specifics may vary by organ type. Tissue Typing Components : Includes HLA-A, HLA-B, and HLA-DR loci. (Option D) Represents an individual's tissue type. Differences by Organ Type Kidney Transplantation : HLA matching is crucial. Liver Transplantation : ABO blood group compatibility is more important than HLA matching. Reference: SRB’s Manual of Surgery, 6th Edition, Page 327, 330, 331.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    },
    {
      "q_no": 25,
      "question": "A 45-year-old male patient undergoes a kidney transplant. Shortly after the procedure, he experiences a rapid onset of graft dysfunction characterized by the destruction of the graft’s vascularization. Which type of rejection does this patient most likely have?",
      "options": {
        "A": "Hyperacute Rejection",
        "B": "Acute Cellular Rejection",
        "C": "Acute Humoral Rejection",
        "D": "Chronic Rejection"
      },
      "correct_answer": "A",
      "explanation": "minutes to hours of transplantation and is characterized by rapid destruction of vascularization due to pre-existing antibodies against the graft. This type of graft rejection is primarily antibody-mediated and is most commonly associated with pre-existing antibodies against the graft. Graft Rejection Overview Graft Rejection : The host's immune system targets and tries to eliminate the transplanted organ. Immunosuppressive Drugs : Used to suppress the immune response and improve graft acceptance. Immune Mechanisms : Involves cellular (T cells) and humoral (antibodies) responses. Stages of Immune Response Sensitization Stage : Initial recognition of the organ as foreign. Non-immunologic injury can worsen the response by increasing antigen presentation and leading to macrophage activation and antibody production. Effector Stage : Coordinated immune attack on the graft by T cells and antibodies. Types of Rejection Type of Rejection Timing Mechanism Characteristics Hyperacute (Option A) Minutes to hours Antibody-mediated Rapid vascular destruction; pre-existing antibodies; common in kidneys. Acute (Option B & D) Within 6 months Cellular & Humoral Cellular (lymphocytes) or humoral (antibodies) response. Chronic (Option D) Months to years after acute rejection Antibody- and cell-mediated Fibrosis and scarring. Specifics: Liver: Vanishing bile duct syndrome Kidney: Chronic allograft nephropathy (fibrosis and glomerulopathy) Factors Contributing to Chronic Rejection Previous acute rejection Hypertension Inadequate immunosuppression Reperfusion injury Extended cold ischemic time Post-transplant infection Treatment of Graft Rejection Assessment and Monitoring : Clinical examination, organ-specific tests, and blood parameters. Kidney : Urine output, creatinine levels, ultrasound, graft biopsy. Liver : Function tests and biopsy. Immunosuppressive drugs Risks : Infection (due to immune suppression) Potential for malignancies Reference: SRB’s Manual of Surgery, 6th Edition, Page 328, 32",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Miscellaneous-Transplantation"
    }
  ]
}
